Published in Clin Cancer Res on November 16, 2010
Mechanisms and insights into drug resistance in cancer. Front Pharmacol (2013) 1.70
Collateral sensitivity as a strategy against cancer multidrug resistance. Drug Resist Updat (2012) 1.53
Targeting MDR in breast and lung cancer: discriminating its potential importance from the failure of drug resistance reversal studies. Drug Resist Updat (2012) 1.23
Epithelial-to-mesenchymal transition and the cancer stem cell phenotype: insights from cancer biology with therapeutic implications for colorectal cancer. Cancer Gene Ther (2014) 1.12
ABC transporters: unvalidated therapeutic targets in cancer and the CNS. Anticancer Agents Med Chem (2010) 1.05
PET and SPECT radiotracers to assess function and expression of ABC transporters in vivo. Curr Drug Metab (2011) 0.95
MDR1 siRNA loaded hyaluronic acid-based CD44 targeted nanoparticle systems circumvent paclitaxel resistance in ovarian cancer. Sci Rep (2015) 0.91
Paclitaxel Through the Ages of Anticancer Therapy: Exploring Its Role in Chemoresistance and Radiation Therapy. Cancers (Basel) (2015) 0.90
Grape seed procyanidin reversal of p-glycoprotein associated multi-drug resistance via down-regulation of NF-κB and MAPK/ERK mediated YB-1 activity in A2780/T cells. PLoS One (2013) 0.89
Reversal of MRP7 (ABCC10)-mediated multidrug resistance by tariquidar. PLoS One (2013) 0.88
ASDCD: antifungal synergistic drug combination database. PLoS One (2014) 0.85
NLLSS: Predicting Synergistic Drug Combinations Based on Semi-supervised Learning. PLoS Comput Biol (2016) 0.85
A comparative small-animal PET evaluation of [11C]tariquidar, [11C]elacridar and (R)-[11C]verapamil for detection of P-glycoprotein-expressing murine breast cancer. Eur J Nucl Med Mol Imaging (2011) 0.84
Prevention of multidrug resistance (MDR) in osteosarcoma by NSC23925. Br J Cancer (2014) 0.84
Development of a cyclin-dependent kinase inhibitor devoid of ABC transporter-dependent drug resistance. Br J Cancer (2013) 0.83
Design and synthesis of human ABCB1 (P-glycoprotein) inhibitors by peptide coupling of diverse chemical scaffolds on carboxyl and amino termini of (S)-valine-derived thiazole amino acid. J Med Chem (2014) 0.80
ABCB1 (MDR1) induction defines a common resistance mechanism in paclitaxel- and olaparib-resistant ovarian cancer cells. Br J Cancer (2016) 0.80
Nanoparticle-mediated drug delivery for treating melanoma. Nanomedicine (Lond) (2015) 0.79
Formulation development of a novel targeted theranostic nanoemulsion of docetaxel to overcome multidrug resistance in ovarian cancer. Drug Deliv (2014) 0.78
Disrupting P-glycoprotein function in clinical settings: what can we learn from the fundamental aspects of this transporter? Am J Cancer Res (2016) 0.78
Combining GRP78 suppression and MK2206-induced Akt inhibition decreases doxorubicin-induced P-glycoprotein expression and mitigates chemoresistance in human osteosarcoma. Oncotarget (2016) 0.76
Chemoresistance and targeted therapies in ovarian and endometrial cancers. Oncotarget (2017) 0.75
Cytochrome P450 and P-Glycoprotein-Mediated Interactions Involving African Herbs Indicated for Common Noncommunicable Diseases. Evid Based Complement Alternat Med (2017) 0.75
The Role of Eukaryotic and Prokaryotic ABC Transporter Family in Failure of Chemotherapy. Front Pharmacol (2017) 0.75
Targeting P-glycoprotein: Investigation of piperine analogs for overcoming drug resistance in cancer. Sci Rep (2017) 0.75
Multidrug resistance in cancer: role of ATP-dependent transporters. Nat Rev Cancer (2002) 15.72
The role of ABC transporters in clinical practice. Oncologist (2003) 3.21
Reduced drug accumulation in multiply drug-resistant human KB carcinoma cell lines. Cancer Res (1985) 3.15
The use of non-parametric methods in the statistical analysis of the two-period change-over design. Biometrics (1972) 2.62
Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer. J Clin Oncol (1999) 2.19
In vitro and in vivo reversal of multidrug resistance by GF120918, an acridonecarboxamide derivative. Cancer Res (1993) 2.15
Pharmacological strategies for overcoming multidrug resistance. Curr Drug Targets (2006) 1.96
In vitro and in vivo reversal of P-glycoprotein-mediated multidrug resistance by a novel potent modulator, XR9576. Cancer Res (2001) 1.95
Phase II trial of docetaxel: a new, highly effective antineoplastic agent in the management of patients with anthracycline-resistant metastatic breast cancer. J Clin Oncol (1995) 1.85
The molecular interaction of the high affinity reversal agent XR9576 with P-glycoprotein. Br J Pharmacol (1999) 1.84
Tumor and host factors that may limit efficacy of chemotherapy in non-small cell and small cell lung cancer. Crit Rev Oncol Hematol (2010) 1.82
Cost-effectiveness of 99mTc-sestamibi in predicting response to chemotherapy in patients with lung cancer: systematic review and meta-analysis. J Nucl Med (2009) 1.75
Docetaxel (Taxotere): an active drug for the treatment of patients with advanced squamous cell carcinoma of the head and neck. EORTC Early Clinical Trials Group. Ann Oncol (1994) 1.56
Breast cancer resistance protein impacts clinical outcome in platinum-based chemotherapy for advanced non-small cell lung cancer. Clin Cancer Res (2004) 1.54
Docetaxel administered on a weekly basis for metastatic breast cancer. J Clin Oncol (2000) 1.41
Phase II study of tariquidar, a selective P-glycoprotein inhibitor, in patients with chemotherapy-resistant, advanced breast carcinoma. Cancer (2005) 1.40
Phase I trial of XR9576 in healthy volunteers demonstrates modulation of P-glycoprotein in CD56+ lymphocytes after oral and intravenous administration. Clin Cancer Res (2000) 1.24
Inhibition of P-glycoprotein (ABCB1)- and multidrug resistance-associated protein 1 (ABCC1)-mediated transport by the orally administered inhibitor, CBT-1((R)). Biochem Pharmacol (2007) 1.19
A phase I study of the P-glycoprotein antagonist tariquidar in combination with vinorelbine. Clin Cancer Res (2009) 1.15
Increased 99mTc-sestamibi accumulation in normal liver and drug-resistant tumors after the administration of the glycoprotein inhibitor, XR9576. Clin Cancer Res (2003) 1.11
Detection of in vivo P-glycoprotein inhibition by PSC 833 using Tc-99m sestamibi. Clin Cancer Res (1997) 1.07
Phase II study of paclitaxel and valspodar (PSC 833) in refractory ovarian carcinoma: a gynecologic oncology group study. J Clin Oncol (2001) 1.07
Predicting chemotherapy response to paclitaxel-based therapy in advanced non-small-cell lung cancer with P-glycoprotein expression. Respiration (2003) 1.04
Phase I and pharmacokinetic study of paclitaxel in combination with biricodar, a novel agent that reverses multidrug resistance conferred by overexpression of both MDR1 and MRP. J Clin Oncol (1998) 1.04
A phase I/II study of infusional vinblastine with the P-glycoprotein antagonist valspodar (PSC 833) in renal cell carcinoma. Clin Cancer Res (2004) 1.02
Effects of MDR1 and MDR3 P-glycoproteins, MRP1, and BCRP/MXR/ABCP on the transport of (99m)Tc-tetrofosmin. Biochem Pharmacol (2000) 1.02
A phase II study of the MDR inhibitor biricodar (INCEL, VX-710) and paclitaxel in women with advanced ovarian cancer refractory to paclitaxel therapy. Gynecol Oncol (2002) 0.99
Multidrug resistance proteins do not predict benefit of adjuvant chemotherapy in patients with completely resected non-small cell lung cancer: International Adjuvant Lung Cancer Trial Biologic Program. Clin Cancer Res (2007) 0.99
Expression of MRP1, BCRP, LRP, and ERCC1 in advanced non-small-cell lung cancer: correlation with response to chemotherapy and survival. Clin Lung Cancer (2009) 0.93
SDZ PSC 833, a non-immunosuppressive cyclosporine: its potency in overcoming P-glycoprotein-mediated multidrug resistance of murine leukemia. Int J Cancer (1992) 0.92
Flow cytometric assay of modulation of P-glycoprotein function in whole blood by the multidrug resistance inhibitor GG918. Clin Cancer Res (1996) 0.92
Phase I study of infusional paclitaxel in combination with the P-glycoprotein antagonist PSC 833. J Clin Oncol (2001) 0.91
99mTc-MIBI SPET in non-small cell lung cancer in relationship with Pgp and prognosis. Eur J Nucl Med Mol Imaging (2002) 0.90
Efflux of rhodamine from CD56+ cells as a surrogate marker for reversal of P-glycoprotein-mediated drug efflux by PSC 833. Blood (1999) 0.86
Semi-quantitative assessment of 99Tcm-sestamibi uptake in lung cancer: relationship with clinical response to chemotherapy. Nucl Med Commun (1997) 0.83
Evaluation of the linearity of docetaxel pharmacokinetics. Cancer Chemother Pharmacol (1998) 0.83
p53 and P-glycoprotein expression do not correlate with survival in nonsmall cell lung cancer: a long-term study and literature review. Mod Pathol (1999) 0.83
Immunohistochemically detected p53 and P-glycoprotein predict the response to chemotherapy in lung cancer. Eur J Cancer (1998) 0.80
P-glycoprotein versus MRP1 on transport kinetics of cationic lipophilic substrates: a comparative study using [99mTc]sestamibi and [99mTc]tetrofosmin. Cancer Biother Radiopharm (2009) 0.79
Structure-activity relationships of tariquidar analogs as multidrug resistance modulators. AAPS J (2009) 0.79
99mTc-Sestamibi scanning with SDZ PSC 833 as a functional detection method for resistance modulation in patients with solid tumours. Anticancer Res (1999) 0.79
Phase I and pharmacokinetic study of escalating dose of docetaxel administered with granulocyte colony-stimulating factor support in adult advanced solid tumors. Clin Cancer Res (2003) 0.78
Technetium-99m MIBI single photon emission computed tomography as an indicator of prognosis for patients with lung cancer-preliminaly report. Ann Nucl Med (2000) 0.78
Comparative study of Tc-99m MIBI and TI-201 SPECT in predicting chemotherapeutic response in non-small-cell lung cancer. Clin Nucl Med (2000) 0.78
Tetrofosmin as predictors of tumour response. Q J Nucl Med (2003) 0.78
Epiphora (excessive tearing) and other ocular manifestations related to weekly docetaxel: underestimated dose-limiting toxicity. Med Oncol (2006) 0.77
Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol (2008) 18.54
Use of proteomic patterns in serum to identify ovarian cancer. Lancet (2002) 16.38
Multidrug resistance in cancer: role of ATP-dependent transporters. Nat Rev Cancer (2002) 15.72
Tumour stem cells and drug resistance. Nat Rev Cancer (2005) 15.21
A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med (2003) 14.59
Delivering affordable cancer care in high-income countries. Lancet Oncol (2011) 12.79
Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proc Natl Acad Sci U S A (2003) 10.71
Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy. Clin Cancer Res (2011) 9.03
A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer. Clin Cancer Res (2006) 7.09
Prognostic factors related to clinical response in patients with metastatic melanoma treated by CTL-associated antigen-4 blockade. Clin Cancer Res (2007) 5.51
Dose-adjusted EPOCH-rituximab therapy in primary mediastinal B-cell lymphoma. N Engl J Med (2013) 4.96
Phase I trial of the histone deacetylase inhibitor, depsipeptide (FR901228, NSC 630176), in patients with refractory neoplasms. Clin Cancer Res (2002) 4.90
Serum proteomic patterns for detection of prostate cancer. J Natl Cancer Inst (2002) 4.50
Cancer drugs in the United States: Justum Pretium--the just price. J Clin Oncol (2013) 4.25
Phase 0 clinical trial of the poly (ADP-ribose) polymerase inhibitor ABT-888 in patients with advanced malignancies. J Clin Oncol (2009) 4.14
Pharmacy education: back to the basics? Pharmacotherapy (2003) 4.11
Tumor progression can occur despite the induction of very high levels of self/tumor antigen-specific CD8+ T cells in patients with melanoma. J Immunol (2005) 3.73
Safety and activity of crizotinib for paediatric patients with refractory solid tumours or anaplastic large-cell lymphoma: a Children's Oncology Group phase 1 consortium study. Lancet Oncol (2013) 3.70
Immunologic and prognostic factors associated with overall survival employing a poxviral-based PSA vaccine in metastatic castrate-resistant prostate cancer. Cancer Immunol Immunother (2009) 3.70
Combining a recombinant cancer vaccine with standard definitive radiotherapy in patients with localized prostate cancer. Clin Cancer Res (2005) 3.57
Antiangiogenic and antitumor effects of bevacizumab in patients with inflammatory and locally advanced breast cancer. J Clin Oncol (2006) 3.53
Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer. J Clin Oncol (2003) 3.38
Combination targeted therapy with sorafenib and bevacizumab results in enhanced toxicity and antitumor activity. J Clin Oncol (2008) 3.32
The role of ABC transporters in clinical practice. Oncologist (2003) 3.21
Randomized phase II trial of docetaxel plus thalidomide in androgen-independent prostate cancer. J Clin Oncol (2004) 3.16
Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma. J Clin Oncol (2009) 3.13
Tumor-induced osteomalacia. Endocr Relat Cancer (2011) 3.13
Randomized, double-blind, placebo-controlled phase IIb trial of the cyclooxygenase inhibitor ketorolac as an oral rinse in oropharyngeal leukoplakia. Clin Cancer Res (2004) 2.95
Combination chemotherapy in advanced adrenocortical carcinoma. N Engl J Med (2012) 2.82
Eighteen-year results in the treatment of early breast carcinoma with mastectomy versus breast conservation therapy: the National Cancer Institute Randomized Trial. Cancer (2003) 2.77
Somatic HIF2A gain-of-function mutations in paraganglioma with polycythemia. N Engl J Med (2012) 2.74
Hemodynamic and functional assessment of patients with sickle cell disease and pulmonary hypertension. Am J Respir Crit Care Med (2007) 2.68
Her-2 overexpression increases the metastatic outgrowth of breast cancer cells in the brain. Cancer Res (2007) 2.66
Phase 2 trial of romidepsin in patients with peripheral T-cell lymphoma. Blood (2011) 2.64
Mitosis is not a key target of microtubule agents in patient tumors. Nat Rev Clin Oncol (2011) 2.61
Cardiac studies in patients treated with depsipeptide, FK228, in a phase II trial for T-cell lymphoma. Clin Cancer Res (2006) 2.61
Superiority of fluorodeoxyglucose positron emission tomography to other functional imaging techniques in the evaluation of metastatic SDHB-associated pheochromocytoma and paraganglioma. J Clin Oncol (2007) 2.60
Medroxyprogesterone acetate elevation of Nm23-H1 metastasis suppressor expression in hormone receptor-negative breast cancer. J Natl Cancer Inst (2005) 2.60
Compressing drug development timelines in oncology using phase '0' trials. Nat Rev Cancer (2007) 2.52
Comparison of 18F-fluoro-L-DOPA, 18F-fluoro-deoxyglucose, and 18F-fluorodopamine PET and 123I-MIBG scintigraphy in the localization of pheochromocytoma and paraganglioma. J Clin Endocrinol Metab (2009) 2.51
Ipilimumab and a poxviral vaccine targeting prostate-specific antigen in metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial. Lancet Oncol (2012) 2.51
Phase II study of dose-adjusted EPOCH and rituximab in untreated diffuse large B-cell lymphoma with analysis of germinal center and post-germinal center biomarkers. J Clin Oncol (2008) 2.51
Metastatic pheochromocytoma/paraganglioma related to primary tumor development in childhood or adolescence: significant link to SDHB mutations. J Clin Oncol (2011) 2.49
Tumor regression and growth rates determined in five intramural NCI prostate cancer trials: the growth rate constant as an indicator of therapeutic efficacy. Clin Cancer Res (2010) 2.45
Phase I study of a vaccine using recombinant vaccinia virus expressing PSA (rV-PSA) in patients with metastatic androgen-independent prostate cancer. Prostate (2002) 2.44
Scientific collaboration results in higher citation rates of published articles. Pharmacotherapy (2006) 2.39
Major cancer regressions in mesothelioma after treatment with an anti-mesothelin immunotoxin and immune suppression. Sci Transl Med (2013) 2.39
Phase I and pharmacokinetic study of MS-275, a histone deacetylase inhibitor, in patients with advanced and refractory solid tumors or lymphoma. J Clin Oncol (2005) 2.36
ABCG2: determining its relevance in clinical drug resistance. Cancer Metastasis Rev (2007) 2.31
Low-intensity therapy in adults with Burkitt's lymphoma. N Engl J Med (2013) 2.31
Dose-adjusted EPOCH chemotherapy for untreated large B-cell lymphomas: a pharmacodynamic approach with high efficacy. Blood (2002) 2.28
Association of serum gamma-glutamyltransferase with arterial stiffness in established coronary artery disease. Angiology (2012) 2.26
Sunitinib does not accelerate tumor growth in patients with metastatic renal cell carcinoma. Cell Rep (2013) 2.24
Effect of lapatinib on the outgrowth of metastatic breast cancer cells to the brain. J Natl Cancer Inst (2008) 2.24
Identification of OATP1B3 as a high-affinity hepatocellular transporter of paclitaxel. Cancer Biol Ther (2005) 2.23
Nelfinavir, A lead HIV protease inhibitor, is a broad-spectrum, anticancer agent that induces endoplasmic reticulum stress, autophagy, and apoptosis in vitro and in vivo. Clin Cancer Res (2007) 2.22
Thalidomide. Lancet (2004) 2.21
A randomized phase II study of concurrent docetaxel plus vaccine versus vaccine alone in metastatic androgen-independent prostate cancer. Clin Cancer Res (2006) 2.20
Lung cysts, spontaneous pneumothorax, and genetic associations in 89 families with Birt-Hogg-Dubé syndrome. Am J Respir Crit Care Med (2007) 2.19
Phase 1 and pharmacologic study of MS-275, a histone deacetylase inhibitor, in adults with refractory and relapsed acute leukemias. Blood (2007) 2.15
Treatment of metastatic melanoma using interleukin-2 alone or in conjunction with vaccines. Clin Cancer Res (2008) 2.15
Erlotinib (Tarceva, OSI-774) antagonizes ATP-binding cassette subfamily B member 1 and ATP-binding cassette subfamily G member 2-mediated drug resistance. Cancer Res (2007) 2.15
Remission in dermatitis herpetiformis: a cohort study. Arch Dermatol (2010) 2.14
Tariquidar (XR9576): a P-glycoprotein drug efflux pump inhibitor. Expert Rev Anticancer Ther (2007) 2.11
The role of tumor histogenesis, FDG-PET, and short-course EPOCH with dose-dense rituximab (SC-EPOCH-RR) in HIV-associated diffuse large B-cell lymphoma. Blood (2010) 2.09
Superiority of 6-[18F]-fluorodopamine positron emission tomography versus [131I]-metaiodobenzylguanidine scintigraphy in the localization of metastatic pheochromocytoma. J Clin Endocrinol Metab (2003) 2.08
Men with low serum cholesterol have a lower risk of high-grade prostate cancer in the placebo arm of the prostate cancer prevention trial. Cancer Epidemiol Biomarkers Prev (2009) 2.06
Glucarpidase, leucovorin, and thymidine for high-dose methotrexate-induced renal dysfunction: clinical and pharmacologic factors affecting outcome. J Clin Oncol (2010) 2.05
Loss of Smad3 in acute T-cell lymphoblastic leukemia. N Engl J Med (2004) 2.05
Analysis of factors associated with outcome in patients with malignant peritoneal mesothelioma undergoing surgical debulking and intraperitoneal chemotherapy. J Clin Oncol (2003) 2.05
Lapatinib (Tykerb, GW572016) reverses multidrug resistance in cancer cells by inhibiting the activity of ATP-binding cassette subfamily B member 1 and G member 2. Cancer Res (2008) 2.04
Genetic counseling and testing in families with hereditary nonpolyposis colorectal cancer. Arch Intern Med (2003) 2.01
Cediranib for metastatic alveolar soft part sarcoma. J Clin Oncol (2013) 1.99
Angiogenesis inhibitors: current strategies and future prospects. CA Cancer J Clin (2010) 1.98
ABCG2: a perspective. Adv Drug Deliv Rev (2008) 1.97
Identification of microRNA-21 as a biomarker for chemoresistance and clinical outcome following adjuvant therapy in resectable pancreatic cancer. PLoS One (2010) 1.96
Prediction of clinical outcome using gene expression profiling and artificial neural networks for patients with neuroblastoma. Cancer Res (2004) 1.96
Prostate Specific Antigen Working Group guidelines on prostate specific antigen doubling time. J Urol (2008) 1.95
Effect of SLCO1B3 haplotype on testosterone transport and clinical outcome in caucasian patients with androgen-independent prostatic cancer. Clin Cancer Res (2008) 1.95